Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 28 | 1,105 | 47% |
| 2020 | 20 | 872 | 49% |
| 2021 | 32 | 1,061 |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 51% of the cases CMS names in Pennsylvania; 22 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 12 | 563−6.5%/yr | −6.5%/yr | 0.3 | 16% | 550 in 2030−0.3%/yr |
| New Jersey | 12 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 205 | 12,153+2.9%/yr | +2.9%/yr | 8.51.2× | 63% | 14,300 in 2030+2.7%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
| 2024 |
| 1,028 |
| 58% |
| 2025 est. | ≈ 970 | – |
| 2026 est. | ≈ 980 | – |
| 51% |
| 2022 | 31 | 956 | 53% |
| 2023 | 27 | 976 | 56% |
| 2024 | 32 | 1,028 | 58% |
| 2025 from claims | – | 966 887–1,022 | 59% |
| 2026 forecast | – | 980 862–1,131 | 59% |
| 2027 forecast | – | 981 839–1,170 | 59% |
| 2028 forecast | – | 983 820–1,203 | 60% |
| 2029 forecast | – | 984 804–1,234 | 60% |
| 2030 forecast | – | 985 789–1,262 | 61% |
In 2025, 3% inpatient hospital, 64% hospital outpatient, 32% surgery center. The share outside the hospital has moved +12 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~980 | ~34 | ~620 | ~330 |
| 2027 · ~980 | ~35 | ~610 | ~340 |
| 2028 · ~980 | ~35 | ~610 | ~340 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 34% (32% in 2025), hospital outpatient about 62% (64% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| 392−5%/yr |
| −5%/yr |
| 0.4 |
| 70% |
| 450 in 2030+2.2%/yr |
| Massachusetts | 5 | 264−7.2%/yr | −7.2%/yr | 0.3 | 15% | 380 in 2030+6.4%/yr |
| New Hampshire | 2 | 101+2.3%/yr | +2.3%/yr | 0.4 | 46% | 190 in 2030+11%/yr |
| 15 |
| 1,231+6.1%/yr |
| +6.1%/yr |
| 0.81.3× |
| 44% |
| 1,540 in 2030+3.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Abbott leads with 41% of company spending on these surgeons in 2025, level with 2024.
In 2025, 10 companies reported engagement with Pennsylvania’s surgeons worth $805K in consulting, speaking, meals and travel tied to these products, about $25K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.